Related Experiment Video
Updated: Jan 9, 2026
Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles
Published on: December 1, 2016
CD44 targeted functionalized nanocarriers for non-small cell lung cancer
Na Zhu1, Ruijuan Guo1, Yanyan Jiang2
1Medical Oncology Department, Yantaishan Hospital, Yantai, Shandong, China.
Abstract:
Non-small cell lung cancer (NSCLC) is a significant worldwide health concern, requiring novel treatment strategies. This review presents the potential of CD44-targeted functionalized nanocarriers as effective tools for treating NSCLC. CD44, a glycoprotein found on surface of cells, is known for being excessively expressed in NSCLC, making it a promising target for targeted drug delivery. The review begins by examining CD44 as a crucial biomarker in NSCLC. The text provides an overview of molecular features of NSCLC. These fundamental concepts provide the framework for comprehending the reasoning behind the focused strategy of medication delivery using nanocarriers. The review discusses the importance of key factors, such as the dimensions, morphology, and electrostatic properties of nanocarriers, in relation to their influence on interactions with CD44 receptors. The review provides an assessment of preclinical and clinical research that has examined the use of CD44-targeted nanocarriers in the treatment of NSCLC. The review further provides an analysis of safety concerns and possible difficulties, like immunogenicity and off-target effects, in relation to CD44-targeted nanocarriers. This review provides helpful guidance to researchers and clinicians who are interested in using CD44-targeted nanocarriers for more precise and efficient therapies of NSCLC.
Insights
CD44-targeted nanocarriers show promise for treating non-small cell lung cancer (NSCLC). This approach leverages CD44 overexpression in NSCLC for precise drug delivery, offering potential for improved therapies.
Area of Science:
- Oncology
- Nanotechnology
- Biomaterials
Background:
- Non-small cell lung cancer (NSCLC) presents a global health challenge necessitating innovative treatments.
- CD44, a cell surface glycoprotein, is significantly overexpressed in NSCLC, identifying it as a key therapeutic target.
- Understanding NSCLC molecular characteristics is crucial for developing targeted drug delivery systems.
Purpose of the Study:
- To review the potential of CD44-targeted functionalized nanocarriers for NSCLC treatment.
- To explore CD44 as a biomarker and its role in targeted drug delivery strategies.
- To guide researchers and clinicians in utilizing nanocarrier-based therapies for NSCLC.
Main Methods:
- Review of preclinical and clinical studies on CD44-targeted nanocarriers in NSCLC.
- Analysis of nanocarrier properties (size, morphology, charge) influencing CD44 receptor interaction.
- Assessment of safety considerations, including immunogenicity and off-target effects.
Main Results:
- CD44-targeted nanocarriers demonstrate potential for effective NSCLC treatment.
- Nanocarrier characteristics significantly impact their interaction with CD44 receptors.
- Preclinical and clinical data support the efficacy of this targeted approach.
Conclusions:
- CD44-targeted nanocarriers offer a promising strategy for precise and efficient NSCLC therapy.
- Careful consideration of nanocarrier design and potential safety issues is essential.
- This targeted approach holds potential for advancing NSCLC treatment paradigms.
